John McIntyre
Principal, Athfield Architects
John (JR) Robson is the General Manager of Bridgewest Ventures, and he is responsible for the early-stage deep technology investment portfolio of the Bridgewest Group in New Zealand. Bridgewest have a very large biotech portfolio across the world, with operations in the US, Australia, and China, and JR works closely with the global biotechnology executives in support of the investments in New Zealand.
JR is a finance and investment professional with over 25 years of investment experience, and he has been intimately involved in the technology start-up community in New Zealand since 2008 through numerous early-stage tech companies, both as a founder and as a director. JR regularly writes and speaks about technology in a number of forums and is heavily involved in the biotech sector through his directorships and governance support, and via his community role with BioTechNZ and as a member of the NZTech Board.
JR also sits on the Board of the One Percent Collective Trust, and organisation that promotes generosity and regular giving, and is a Life Member of the Child Cancer Foundation, an award he received in recognition of his charitable work in support of children and their families that are affected by cancer.
Principal, Athfield Architects
Corporate Development Manager, Aroa Biosurgery
CEO, RTDS Group
Chief Technology Officer, Vaxxas
© 2023, BioTech New Zealand Association.
All rights reserved.